Loading...
The Official Journal of Chinese Anti-Cancer Association
Editors-in-Chief: XZ Wu, PhD. Prof.
ISSN 2538-015X
93TMR Cancer (ISSN 2538-015X) is a quarterly open access journal with a comprehensive peer review policy, and a rapid publication process. TMR Cancer features the best in clinical and laboratory-based research on all aspects of cancer, medicine and cancer associated technologies. It is dedicated to report the research progress in clinical efficacy, action mechanism and theoretical research on oncology. It set up basic research, clinical research, case reports, comment, review, theoretical discussion, and drug research columns. It seeks to promote international communication focusing on the latest developments, trends, experiences and achievements on cancer in clinical practice and scientific research. ... More

Current Issue     03 September 2019, Volume 2 Issue 3 Previous Issue   
For Selected: View Abstracts Toggle Thumbnails

Integrative Oncology
Research progress in the treatment of colorectal cancer in classical prescriptions
Shi-Yun Shao, Qi Li
93TMR Cancer. 2019, 2 (3): 200-205.   https://doi.org/10.12032/TMRC201800056
Abstract ( 67 )   HTML ( 6 )     PDF (589KB) ( 28 )  

Highlights

Traditional Chinese medicine is an important tumor-assisted treatment.

Classical formula has a good effect in colorectal treatment, but the mechanism is not clear.

Comments

Classical Chinese medicine prescriptions are widely used in cancer treatment. Although obvious therapeutic effects have been observed in clinical practice, laboratory evidence is still lacking. Clinically effective prescriptions may become the research direction for the development of cancer therapeutic drugs.

Abstract

ShanghanZabingLun, an acient book of Chinese medicine that published in Han dynasty (219 C.E.), is the first monograph in China that has the principles of prescription and treatment. Modern physicians flexibly applied many classical prescriptions recorded on this acientd book, such as BanxiaXiexin decoction, DaChengqi decoction, YiyiFuziBijiang decoction and Wumeipill for the treatment of colorectal cancer and its complications, and made some progress in clinical and experimental research. Studies have shown that classical prescriptions alone or in combination with other therapies can improve immunity, prevent cancer from recurrence and metastasis, reduce the side effects of anticancer drugs, improve quality of life, and prolong the survival of cancer patients. However, the current clinical and mechanistic studies on the treatment of classical prescriptions still need to explore in depth. This study aims to summarize the clinical and research progress in the treatment of colorectal cancer with classical prescriptions in recent years.

The differences and similarities between regional ethnic medicine and traditional Chinese medicine in the prevention and treatment of cancer pain
Hui-Li Shui, Zhu Yang , Feng-Xi Long , Wen-Qi Huang , Bing Yang , Zhen Zhang , Dong-Xin Tang
93TMR Cancer. 2019, 2 (3): 206-211.   https://doi.org/10.12032/TMRC201800044
Abstract ( 657 )   HTML ( 7 )     PDF (577KB) ( 125 )  

Highlights

Regional ethnic medicine (REM) and traditional Chinese medicine (TCM) have unique experience in the treatment of cancer pain.

There are many different aspects of the treatment of cancer pain in REM and TCM.

Comments

TCM and REM are important cancer-assisted treatments in China. Especially for the treatment of cancer pain, TCM and REM are important alternatives.

Abstract

REM and TCMare both important parts of traditional medicine in China, and they have their own characteristics in the understanding and prevention of diseases. This article compares the understanding, the theoretical prevention and treatment guidance and the clinical application of the REM and TCMon the cancer pain.

Clinical Cancer Research
Combination of Chinese and Western medicine in the treatment of aggressive angiomyxoma: a case report
Yan Liu , Zheng-Wei Jiao, Teng Huang , Si-Ning Ha , Yan-Bo Zuo , Xiao-Shi Jin
93TMR Cancer. 2019, 2 (3): 212-215.   https://doi.org/10.12032/TMRC201800053
Abstract ( 78 )   HTML ( 3 )     PDF (369KB) ( 42 )  

Highlights

Although aggressive angiomyxoma (AAM) has some characteristics of malignant tumors, it does not cause distant metastasis.

Surgery combined with traditional Chinese medicine treatment may be a new way to treat AAM.

Comments

Aggressive angiomyxoma(AAM) is a tumor that occurs mainly in women, and its mechanism and treatment are still in the exploratory stage. Traditional Chinese medicine may exert a certain effect in the treatment of AAM. But the mechanism that works is still in need of further laboratory research.

Abstract

Aggressive angiomyxoma (AAM) is a rare soft tissue tumor. Invasiveness and recurrence are important clinical features of AAM. A patient with recurrent AAM was admitted to the hospital.At present, the treatment for AAM is still based on surgerybecause it does not have lymph nodes and distant metastasis. Moreover, chemotherapy is of little significance. Traditional Chinese medicine believes the formation of tumor is related to blood stasis, so after surgery, a Chinese medicine called Xue-Shuan-Tong was used to improve blood circulation and disperses stasis. The drainage tube was removed on the 5th day after the operation and achieved a good wound healing. This article analyzes and demonstrates the pathogenesis of female vulvar invasive angiomyxoma from the perspective of modern medicine and traditional medicine, in order to provide a better understanding of the disease.

The clinical efficacy analysis of radiofrequency ablation combined with chemotherapy in treating late non-small cell lung cancer
Ying-Ying Liu , Feng Xu
93TMR Cancer. 2019, 2 (3): 216-221.   https://doi.org/10.12032/TMRC201800055
Abstract ( 34 )   HTML ( 5 )     PDF (714KB) ( 6 )  

Highlights

CT-guided radiofrequency ablation combined with chemotherapy may be one effective method for the treatment of advanced non-small cell lung cancer (NSCLC).

Radiofrequency ablation is a precise treatment,which may improve disease control rate and the life quality of patients with NSCLC.

Comments

At present, the research on the combined treatment of NSCLC is still limited, and the treatment effect is not clear.At present, the therapeutic effect of combination therapy on NSCLC requires further clinical validation evidence. This article provides clinical evidence for the role of radiotherapy combined with chemotherapy in the treatment of advanced NSCLC.

Abstract

Objective: To study the short-term efficacy and improvement effect on the quality of life of CT guided radiofrequency ablation(RFA) in treating late non-small cell lung cancer. Methods: 317 patients with non-small cell lung cancer (87 cases in the observation group and 230 cases in the control group) were selected for propensity score matching, with a matching tolerance of 0.05, and 42 pairs were successfully paired. The changes in chest enhanced CT before and 3 months after treatment and the quality of life measurement scale EORTC QLQ-C30 in Chinese version were evaluated. Results: The disease control rate of the observation group was 88.09%, which was significantly higher than that of the control group (61.91%). The functional and symptom scores of the two groups after treatment were significantly better than those before treatment, and the indicators of the observation group after treatment were better than those of the control group (P< 0.05). Conclusion: CT-guided radiofrequency ablation combined with chemotherapy is safe and effective in the treatment of NSCLC, which can control local tumor progression, reduce tumor burden, and improve the quality of life of patients with advanced NSCLC.

Cancer Biology
Treatment of undifferentiated thyroid carcinoma with darafini and trametinib:a case report and literature review
Nan Nan , Tao Chi , Xiao-Juan Yan
93TMR Cancer. 2019, 2 (3): 222-226.   https://doi.org/10.12032/TMRC201800057
Abstract ( 59 )   HTML ( 2 )     PDF (395KB) ( 21 )  

Highlights

The treatment of undifferentiated thyroid cancer is still a problem to be explored.

Combination therapy with drugs may be a new strategy for the treatment of undifferentiated thyroid cancer.

Comments

Many patients with undifferentiated thyroid cancer have no significant response to treatment, which is an important cause of tumor progression and death in patients. Genetic testing and the use of targeted drugs against mutant genes may be a viable approach to the treatment of undifferentiated thyroid cancer.

Abstract

Undifferentiated thyroid carcinoma progresses rapidly and has a poor prognosis. The median progression-free survival is only about half a year, and the effect of conventional radiotherapy and chemotherapy is poor. Some patients may be associated with BRAF V600E mutation. Dabrafenib and trametinib were approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations. The combination of the two may make patients receive a better benefit. A phase III clinical trial showed that in patients with advanced malignant melanoma with positive BRAF-V600E mutations, the combination of dabrafenib and trametinib can effectively improve progression-free survival and overall survival in patients.This article describes a case describing a patient with BRAF V600E-mutated thyroid undifferentiated carcinoma that was treated with darafini and trimetinib, and the relevant literature on the combination of the two drugs was analyzed.

TMR Data ExpandedMore

NoticesMore

HighlightsMore
Online FirstMore
    Please wait a minute...
  • 2019-08-17

    Null links between vitamin B6 and B12 intake and occurrence risk of lung cancer: a meta-analysis 
    ...
    Vitamin B6 and B12 are involved in many biochemical reactions and might play a role in carcinogenesis. We summarized the evidences linking vitamin B6 and B12 to occurrence risk of lung cancer and conducted a meta-analysis of the relationship between vitamin B6 and B12 intake and the risk of lung cancer. Fixed-effect meta-analysis was used to calculate pooled relative risks (RRs) and their 95% confidence intervals (CIs). We identified four observational studies (participants, n = 206,290; cases, n = 1,134) and three randomized controlled trials (RCTs; participants, n = 97,569; cases, n = 952). Vitamin B6 and B12 supplementary was not statistically significantly associated with occurrence risk of lung cancer [124/11926 (1.04%) vs. 73/8497 (0.86%), RR = 1.06, 95% CI = 0.78-1.43, P = 0.71]. A consistent association was also observed, findings from RCTs did not support a protective effect of vitamin B6 and B12intake orally decrease the risk of lung cancer occurrence (HR = 1.13, 95% CI = 0.86-1.50, P = 0.39). For the women, there was no confirmed evidence demonstrated vitamin B intake can decrease the occurrence risk of lung cancer across the subgroup analyses (HR = 0.96, 95% CI = 0.80-1.16, P = 0.99). Dietary vitamin B6 and B12 intake also had no influence on occurrence risk of lung cancer in difference doses and intake duration. In conclusion, no confirmed links were found between vitamin B6 and B12 intake and risk of lung cancer occurrence....
    Li-Ping Shen, Rong Li, Ya-Juan Cao
Call for PaperMore